# SECURITIES AND EXCHANGE COMMISSION <br> Washington D.C. 20549 

## Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending April 2010

## GlaxoSmithKline ple

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

[^0]
# Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K 

Securities Exchange Act of 1934.

## Yes No x

--

## Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons


#### Abstract

I give below details of an increase in interests in the Ordinary shares of GlaxoSmithKline plc in respect of the personal holdings of the under-mentioned persons at a price of $£ 12.75$ per Ordinary share, following the re-investment of the dividend paid to shareholders on 8 April 2010.


Mr A P Witty ..... 862
Mrs C M Witty ..... 491
Mr J S Heslop ..... 257
Mr D Learmouth ..... 266
Dr D Pulman ..... 223
Mrs C R Pulman ..... 74

The Company and the above named persons were advised of this information on 12 April 2010.
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell
Company Secretary
12 April 2010

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

Victoria Whyte
Authorised Signatory for and on behalf of GlaxoSmithKline plc


[^0]:    Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the

